Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Lisa Salvatore et al.|The Lancet Oncology|2022Cited by 268
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73